Trial · NCT00753012
Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
NCT00753012, Phase 4, Completed, Massachusetts General Hospital; results first posted 2012-09-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults. Trials, record NCT00753012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00753012
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults
- NCT number
- NCT00753012
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 24 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Lisdexamfetamine
- First posted
- 2008-09-16
- Last updated
- 2012-09-24
- Results first posted
- 2012-09-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Left Ventricle Size | 3-6 months | Size of the heart's left ventricle chamber (Left Ventricular End Diastolic Dimension; LVEDD) following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE) |
| Primary | Cardiac Function Index (E/A Ratio) | 3-6 months | Left ventricle diastolic function index, following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE) |
| Primary | Blood Pressure at Maximum Exertion | 3-6 months | Diastolic blood pressure (DBP) at maximum exertion following 3-6 months of stimulant medication, according to cardiopulmonary exercise testing (CPET) |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Left Ventricle Size | 3-6 months | 14 subjects completed endpoint TTE; one HTN subject missed the scheduled endpoint TTE appointment. | mm | MEAN |
| PRIMARY | Cardiac Function Index (E/A Ratio) | 3-6 months | cm/sec/cm/sec | MEAN | |
| PRIMARY | Blood Pressure at Maximum Exertion | 3-6 months | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Left Ventricle Size | Normotensive Adults With ADHD | 44.42 | Standard Deviation 7.07 | mm | |
| Left Ventricle Size | Primary Hypertensive Adults With ADHD | 43.57 | Standard Deviation 6.13 | mm | |
| Cardiac Function Index (E/A Ratio) | Normotensive Adults With ADHD | 1.38 | Standard Deviation 0.48 | cm/sec/cm/sec | |
| Cardiac Function Index (E/A Ratio) | Primary Hypertensive Adults With ADHD | 1.36 | Standard Deviation 0.84 | cm/sec/cm/sec | |
| Blood Pressure at Maximum Exertion | Normotensive Adults With ADHD | 80.43 | Standard Deviation 11.97 | mmHg | |
| Blood Pressure at Maximum Exertion | Primary Hypertensive Adults With ADHD | 85.00 | Standard Deviation 8.07 | mmHg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Normotensive Adults With ADHD | 15 | |
| Overall Study | STARTED | Primary Hypertensive Adults With ADHD | 9 | |
| Overall Study | COMPLETED | Normotensive Adults With ADHD | 7 | |
| Overall Study | COMPLETED | Primary Hypertensive Adults With ADHD | 8 | |
| Overall Study | NOT COMPLETED | Normotensive Adults With ADHD | 8 | |
| Overall Study | NOT COMPLETED | Primary Hypertensive Adults With ADHD | 1 |
Source ClinicalTrials.gov
Adverse events82
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | anxiety | Psychiatric disorders | Normotensive Adults With ADHD | 2 | 14 | 23 |
| other | anxiety | Psychiatric disorders | Primary Hypertensive Adults With ADHD | 3 | 8 | 39 |
| other | back pain | General disorders | Normotensive Adults With ADHD | 2 | 14 | 7 |
| other | back pain | General disorders | Primary Hypertensive Adults With ADHD | 0 | 8 | 0 |
| other | blind spot | Eye disorders | Normotensive Adults With ADHD | 0 | 14 | 0 |
| other | blind spot | Eye disorders | Primary Hypertensive Adults With ADHD | 1 | 8 | 14 |
| other | blurred vision | Eye disorders | Normotensive Adults With ADHD | 1 | 14 | 3 |
| other | blurred vision | Eye disorders | Primary Hypertensive Adults With ADHD | 0 | 8 | 0 |
| other | cold symptoms | General disorders | Normotensive Adults With ADHD | 5 | 14 | 18 |
| other | cold symptoms | General disorders | Primary Hypertensive Adults With ADHD | 1 | 8 | 7 |
1 to 10 of 82Source ClinicalTrials.gov
See all 82 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Normotensive Adults With ADHD | ||
| Total, all-cause mortality | Primary Hypertensive Adults With ADHD | ||
| Total, other adverse events | Normotensive Adults With ADHD | 11 | 14 |
| Total, other adverse events | Primary Hypertensive Adults With ADHD | 8 | 8 |
| Total, serious adverse events | Normotensive Adults With ADHD | 0 | 14 |
| Total, serious adverse events | Primary Hypertensive Adults With ADHD | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Normotensive Adults With ADHD vs Primary Hypertensive Adults With ADHD: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00753012
GET https://conductscience.org/api/trials/v1/NCT00753012/events?page=2